MUSE could also be used to regulate the production of erythropoietin (EPO) for treating anemia associated with chronic kidney disease56 using the engineered muscle tropism serotype MyoAAV after systemic administration57, which could avoid the induction of high plasma EPO levels linked to elevated risk for cardiovascular complications58. The gene discussed is EPO; the disease is anemia.